Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for NK Checkpoint Inhibitor Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KIR2DL2/CD158b1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KIR2DL2 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed for native glycosylation. |
View KIR2DL2 Products |
| Gene Delivery | KIR2DL2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based functional assays. |
View KIR2DL2 Products |
| Benchmark Ab | Anti-KIR2DL2/3 Recombinant Antibody (Lirilumab Biosimilar) Recombinant positive control for binding and blocking validation. |
View KIR2DL2 Products |
| Validator | KIR2DL2 siRNA Set For target knockdown verification in primary NK cells or cell lines. |
View KIR2DL2 Products |
| Related Target A | KIR2DL1 Inhibitory homolog; critical for cross-reactivity and selectivity profiling. |
View KIR2DL1 Products |
| Related Target B | KIR2DS2 Activating homolog with high sequence identity; essential for counter-screening to avoid off-target activation. |
View KIR2DS2 Products |
| Related Target C | HLA-C Natural ligand for KIR2DL2; required for ligand-blocking and functional assay setups. |
View HLA-C Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High sequence homology with activating receptor KIR2DS2 (>97% ECD identity) | High-purity recombinant KIR2DL2, KIR2DL3, and KIR2DS2 proteins available for precise selectivity screening. |
| Conformation-dependent ligand binding to HLA-C | HEK293 expressed KIR2DL2-Fc fusion preserving native post-translational modifications and tertiary folding. |
| Lack of reliable positive control antibodies | Sequence-verified Lirilumab clinical benchmark antibody (biosimilar) included in the catalog. |
| High rate of false positives in screening | Sequence-verified siRNA knockdown validation sets to confirm target-specific binding. |
Live KIR2DL2/CD158b1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KIR2DL2/CD158b1 therapeutics is intensifying, with major players shifting focus from traditional monospecific mAbs to multi-specific NK cell engagers (NKCEs) and combination regimens. As first-generation therapies like Lirilumab (pan-KIR2D) pave the way in clinical trials, the next wave of R&D is targeting highly selective or multi-functional molecules that can precisely modulate NK cell activity without triggering unwanted auto-immune reactions or off-target activation via activating KIR homologs.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Innate Pharma, Bristol Myers Squibb | Solid Tumors, Hematological Malignancies | Ligand-blocking assays (Need high-purity ECD-Fc and HLA-C proteins) |
| Multi-specific NK Cell Engagers | Sanofi, Affimed | Relapsed/Refractory Myeloma, Lymphoma | Cross-reactivity screening (Need KIR2DL1/2/3 and KIR2DS2 panels) |
| Cell Therapies (CAR-NK) | Academic Institutions, Biotech Startups | Advanced Solid Tumors | Stable target expression (Need Lentivirus for target cell line validation) |